Point Therapeutics Announces Preclinical Data Presentations at Upcoming American Association of Cancer Research Annual Meeting

  
    
  
  
    
      Point Therapeutics, Inc. (NASDAQ: POTP) today reported the upcoming 
      presentation of preclinical data at the 2007 Annual Meeting of the 
      American Association for Cancer Research (AACR) taking place in Los 
      Angeles, California, April 14-18, 2007. The AACR poster presentations 
      report on preclinical studies on talabostat’s 
      novel mechanism of action.
    
    
      Additional details for the AACR presentations are as follows:
    
    
      Presentation Date and Time: Monday, April 16, 2007, 8:00 AM -12:00 PM PT
    
    
      Abstract #1894: Immune mechanisms of action of talabostat: a dipeptidyl 
      peptidase targeted anti-tumor agent
    
    
      Presentation Date and Time: Wednesday, April 18, 2007, 8:00 AM -12:00 PM 
      PT
    
    
      Abstract #5622: The anti-tumor potential of inhibitors of the DASH 
      proteases in a mouse model of human breast cancer
    
    
      The posters associated with the abstracts will be available on the Point 
      Therapeutics’ web site at www.pther.com 
      immediately following their presentation.
    
    
      About Point Therapeutics, Inc.:
    
    
      Point is a Boston-based biopharmaceutical company currently studying its 
      lead product candidate, talabostat, in two Phase 3 double blind, 
      placebo-controlled trials in non-small cell lung cancer and in a Phase 2 
      trial in combination with gemcitabine in metastatic pancreatic cancer. 
      Point has also studied talabostat in several Phase 2 trials, including 
      as a single-agent in metastatic melanoma, in combination with cisplatin 
      in metastatic melanoma and in combination with rituximab in advanced 
      chronic lymphocytic leukemia.